Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEN-866 in advanced solid malignancies
NCT03221400Phase 2Unknown
- Sponsor
- Tarveda Therapeutics
- Start
- Aug 2017
- Primary completion
- Jan 2023
- Modality
- Miniature drug conjugate
- Countries
- 1
01
Overview
Phase 2, open-label trial of locnartecan in malignant solid tumor, small cell lung cancer (SCLC), gastric adenocarcinoma and 7 more (4 arms), sponsored by Tarveda Therapeutics. Primary endpoints: Incidence of Dose-Limiting Toxicities at 28 days, Incidence of treatment related adverse events and 2 more. Status: unknown.
02
Drugs
locnartecan
03
Conditions
malignant solid tumorsmall cell lung cancer (SCLC)gastric adenocarcinomagastroesophageal junction adenocarcinomapancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03221400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03221400.